Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab. [electronic resource]
Producer: 20150730Description: 10280-92 p. digitalISSN:- 1949-2553
- Adult
- Aged
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Bevacizumab
- Boronic Acids -- administration & dosage
- Bortezomib
- Breast Neoplasms -- drug therapy
- Carcinoma, Renal Cell -- drug therapy
- Fatigue -- etiology
- Female
- Humans
- Hypoxia-Inducible Factor 1, alpha Subunit -- antagonists & inhibitors
- Kidney Neoplasms -- drug therapy
- Magnetic Resonance Imaging
- Male
- Middle Aged
- Neoplasm Staging
- Neovascularization, Pathologic -- drug therapy
- Proteasome Endopeptidase Complex -- drug effects
- Pyrazines -- administration & dosage
- Thrombocytopenia -- etiology
- Treatment Outcome
- Vascular Endothelial Growth Factor A -- immunology
- Vascular Endothelial Growth Factor Receptor-2 -- metabolism
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.